Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Ensayo IGC-AD1 sobre la agitación en la demencia debida a la enfermedad de Alzheimer (CALMA)

28 de septiembre de 2026 actualizado por: IGC Pharma, LLC

Un ensayo de fase 2, multicéntrico, doble ciego, aleatorizado, controlado con placebo, de la seguridad y eficacia de IGC-AD1 sobre la agitación en participantes con demencia debido a la enfermedad de Alzheimer

The purpose of this study is to assess the efficacy of the oral medication IGC-AD1, a THC-based (Delta-9-Tetrahydrocannabinol) formulation administered twice a day on Agitation in patients with mild to severe dementia from Alzheimer's.

Descripción general del estudio

Descripción detallada

CALMA is a multi-center, double-blind, randomized, placebo-controlled clinical trial. The study targets participants aged 60 and older with mild to severe Alzheimer's dementia who have exhibited clinically significant agitation for at least two weeks prior to enrollment. Agitation caused by other conditions or transient symptoms must be ruled out. Eligibility is determined by a baseline Neuropsychiatric Inventory (NPI-12), Agitation subscale score of ≥4 and the International Psychogeriatric Association (IPA) criteria for agitation.

The investigational medication is an oral solution containing two active ingredients: delta-9 tetrahydrocannabinol (THC) and melatonin. The treatment is administered for 42 days, followed by a two-day taper period at the end of the study.

Safety oversight includes daily calls on days 2, 3, and 4, transitioning to calls every third day thereafter. These calls will review study partners logbook entries, changes in concomitant medications, and adverse events.

The primary objective of the study is to evaluate the efficacy of IGC-AD1 on agitation, measured by changes in the Cohen-Mansfield Agitation Inventory (CMAI) scores from baseline to the End of treatment (EOT). The secondary objective is to assess efficacy by examining CMAI score changes from baseline to week two. Additionally, exploratory objectives are outlined in separate documentation.

Blood samples will be collected during the trial for sparse pharmacokinetic (PK) analysis, blood-based CNS biomarker, and genotyping.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

164

Fase

  • Fase 2

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • British Columbia
      • Victoria, British Columbia, Canadá, V8R 1J8
        • Island Health Authorities
    • Ontario
      • Hamilton, Ontario, Canadá, L8M 1W9
        • Hamilton Health Sciences , Mcmaster University
      • Toronto, Ontario, Canadá, ON M6A 2E1
        • Baycrest Academy for Research and Education , University of Toronto
    • Quebec
      • Montreal, Quebec, Canadá, H4H 1R3
        • Douglas Hospital Research Center, McGill university
    • Florida
      • Maitland, Florida, Estados Unidos, 32751
        • ClinCloud, LLC
      • Melbourne, Florida, Estados Unidos, 32940
        • ClinCloud, LLC
      • Miami, Florida, Estados Unidos, 33133
        • Visionary Investigators Network
      • Miami, Florida, Estados Unidos, 33137
        • Miami Jewish Health
      • Miami, Florida, Estados Unidos, 33125
        • Central Miami Medical Institute
      • Port Charlotte, Florida, Estados Unidos, 33952
        • Neurostudies Inc.
      • Tampa, Florida, Estados Unidos, 33613
        • University of South Florida Department of Psychiatry and Behavioral Neurosciences
    • Louisiana
      • Metairie, Louisiana, Estados Unidos, 70006
        • Tandem Clinical Research GI, LLC
    • Maryland
      • Baltimore, Maryland, Estados Unidos, 21237
        • MedStar Franklin Square Medical Center Neurology
      • Clinton, Maryland, Estados Unidos, 20735
        • Medstar Southern Maryland Hospital Center
      • Olney, Maryland, Estados Unidos, 20832
        • Medstar Montgomery Medical Center
    • Missouri
      • St Louis, Missouri, Estados Unidos, 63128
        • Tekton Research LLC
    • New York
      • Amherst, New York, Estados Unidos, 02459
        • Dent Neurologic Institute
      • Brooklyn, New York, Estados Unidos, 11229
        • Integrative Clinical Trials, LLC
      • Syracuse, New York, Estados Unidos, 13210
        • Ichor Research
    • Oklahoma
      • Oklahoma City, Oklahoma, Estados Unidos, 73112
        • Lynn Health Science Institute (LHSI)
    • Rhode Island
      • Providence, Rhode Island, Estados Unidos, 02906
        • Butler Hospital, Brown University
    • Texas
      • Austin, Texas, Estados Unidos, 78757
        • Senior Adults Specialty Research
      • Dallas, Texas, Estados Unidos, 75231
        • Kerwin Medical Center
      • Dallas, Texas, Estados Unidos, 75231
        • Baylor Scott and White Research Institute
    • Virginia
      • Richmond, Virginia, Estados Unidos, 23219
        • Dominion Medical Associates, Inc.
      • Bayamón, Puerto Rico, 00961
        • SCB Research Center Corp
      • Rio Piedras, Puerto Rico, 00935
        • The Alliance, Medical Sciences Campus University of Puerto Rico
    • Bayamón
      • Bayamón, Bayamón, Puerto Rico, 00961
        • Instituto Sanacoop

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

60 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

To be eligible to participate in this study, the participant must meet all the following criteria:

Inclusion Criteria

  1. Participant and/or Caregiver must provide a signed and dated ICF prior to any study procedures.

  2. Must have a Caregiver who is able and willing to comply with all required study procedures.

  3. The Caregiver must be known to the Participant and must be able to use electronic devices such as a cell phone, video conference over a laptop or cell phone, weighing scale, and be able to learn to take blood pressure, among others.

  4. Based on local practice, Participants that cannot consent may have Caregiver's consent provided the Caregiver has among others a) Power of Attorney, b) is a spouse, or c) a sibling or d) a child or e) a close relation. The practice of accepting consent must be consistent with established practice at the site and jurisdiction.

  5. Participants must consent to CYP450 and apolipoprotein E (ApoE) genotyping, and pharmacokinetics.

  6. Diagnosis of AD by NIA-AA criteria

  7. Clinically significant Agitation assessed by:

    1. NPI (Agitation) ≥ 4
    2. The presence of clinically significant, persistent Agitation based on the IPA definition (Appendix C) rather than those with recent onset and occasional symptoms, and
    3. Agitation not attributable to another psychiatric disorder, suboptimal care conditions, other underlining medical condition, or the physiological effects of a substance.
  8. Negative drug screen, except for benzodiazepines if Participant has been using them in stable doses for at least 3 months before screening.

  9. All medications used for behavioral symptoms should be consistent for at least 6 weeks before screening, with allowance for dose changes up to 25%.

  10. Women must be of no childbearing potential (postmenopausal, defined as cessation of menses for at least 12 months, without an alternative medical cause for amenorrhea) or surgically sterile (hysterectomy, bilateral oophorectomy, or bilateral tubal ligation)).

An individual who meets any of the following criteria will be excluded from participation in this study:

Exclusion Criteria

  1. Prior adverse reaction to cannabinoids or to any component of Study Drug (IGC-AD1 and placebo).
  2. Serious or unstable medical illness, including cardiovascular, hepatic, renal, respiratory, endocrine, neurologic, or hematologic disease, which might confound assessment of safety outcomes.
  3. History of seizures, schizophrenia, or bipolar disorder.
  4. Has participated in an investigational drug or device study within 30 days prior to study start.
  5. Urine drug screen positive for drug use, except for benzodiazepines if Participant was using them previously and their dose had remained stable for at least six weeks before screening.
  6. History of Alcohol and Drug use disorder, within one year prior to enrollment.
  7. Hypertension: Participants with a history of uncontrolled hypertension as determined by the PI and Participants with a hypertensive crisis in the six months prior to enrollment.
  8. Falls: Participants with a history of recurrent falls defined as more than two falls in the six-month period prior to enrollment and a history of falls resulting in injuries or associated with a new acute illness, loss of consciousness, fever, or abnormal blood pressure (Fuller et al., 2000).

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Triple

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador activo: Active Comparator: IGC-AD1Active

IGC-AD1-Active, oral solution with two APIs (THC and melatonin).

A non-sterile solution for oral administration.

Otros nombres:
  • Activo
Comparador de placebos: Placebo Comparator: IGC-AD1 Placebo

IGC-AD1-Placebo, oral solution similar to Active in color, taste, and texture, with excipients but without APIs.

A non-sterile solution for oral administration similar in color and texture to the Active.

Otros nombres:
  • Placebo

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Agitation
Periodo de tiempo: Baseline to week six

Change in mean Cohen Mansfield Agitation Inventory (CMAI) score

Baseline to week six

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Acute Agitation
Periodo de tiempo: Baseline to week two

Change in mean Cohen Mansfield Agitation Inventory (CMAI) score

Baseline to week two

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Agitation at week four
Periodo de tiempo: Baseline to week four

Change in mean Cohen Mansfield Agitation Inventory (CMAI) score

Baseline to week four
Participant overall wellbeing
Periodo de tiempo: Baseline to weeks two and six

Change in the Clinical Global Impression Scale (CGI)

Baseline to weeks two and six
Participant executive functions
Periodo de tiempo: Baseline to week six

Change in Mini-Mental State Examination (MMSE2) score

Baseline to week six
Depression
Periodo de tiempo: Baseline to weeks two, four, and six

Change in mean Cornell Scale for Depression in Dementia (CSDD) score

Baseline to weeks two, four, and six
Neuropsychiatric symptoms
Periodo de tiempo: Baseline to weeks two, four, and six

Change in mean Neuropsychiatric Inventory (NPI-12) score

Baseline to weeks two, four, and six
Participant quality of life
Periodo de tiempo: Baseline to weeks two, four and six

Change in mean Quality of Life in Alzheimer's Disease (QOL-AD) score

Baseline to weeks two, four and six
Caregiver burden
Periodo de tiempo: Baseline to weeks two and six

Change in mean Zarit Burden Interview (ZBI) score

Baseline to weeks two and six
Psychotropic drugs
Periodo de tiempo: Baseline to six weeks

Change in type and dosage of psychotropic drugs

Baseline to six weeks
CYP2C9 polymorphisms on agitation
Periodo de tiempo: Baseline to weeks two, four and six

Change in mean Cohen Mansfield Agitation Inventory (CMAI) score for each type of metabolizer group (*1/*1, *1/*3, etc.)

Baseline to weeks two, four and six

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

11 de octubre de 2022

Finalización primaria (Estimado)

1 de noviembre de 2026

Finalización del estudio (Estimado)

1 de noviembre de 2026

Fechas de registro del estudio

Enviado por primera vez

14 de septiembre de 2022

Primero enviado que cumplió con los criterios de control de calidad

14 de septiembre de 2022

Publicado por primera vez (Actual)

16 de septiembre de 2022

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

30 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

28 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

producto fabricado y exportado desde los EE. UU.

Sí

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir